Verve Therapeutics, Inc.
NASDAQ:VERV
5.46 (USD) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 6.692 | 5.695 | 5.144 | 3.117 | 2.093 | 1.404 | 1.012 | 0.929 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 1.667 | 1.632 | 1.517 | 3.199 | 3.026 | 2.759 | 2.553 | 1.997 | 1.148 | 1.013 | 0.969 | 1.757 | 0.357 | 0.294 | 0 | 0 | 0 | 0 |
| Gross Profit
| 5.025 | 4.063 | 3.627 | -0.082 | -0.933 | -1.355 | -1.541 | -1.068 | -1.148 | -1.013 | -0.969 | -1.757 | -0.357 | -0.294 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.751 | 0.713 | 0.705 | -0.026 | -0.446 | -0.965 | -1.523 | -1.15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 50.984 | 48.376 | 46.811 | 43.765 | 47.26 | 47.11 | 37.284 | 35.197 | 33.125 | 24.49 | 25.939 | 17.495 | 13.423 | 11.345 | 15.576 | 7.618 | 5.654 | 6.523 |
| General & Administrative Expenses
| 14.547 | 14.163 | 12.281 | 11.686 | 13.416 | 12.553 | 11.438 | 9.592 | 9.067 | 7.435 | 6.601 | 6.007 | 3.541 | 2.716 | 2.024 | 1.354 | 1.032 | 0.846 |
| Selling & Marketing Expenses
| -1.667 | -1.632 | -1.517 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 12.88 | 12.531 | 10.764 | 11.686 | 13.416 | 12.553 | 11.438 | 9.592 | 9.067 | 7.435 | 6.601 | 6.007 | 3.541 | 2.716 | 2.024 | 1.354 | 1.032 | 0.846 |
| Other Expenses
| 1.671 | 0.078 | -0.713 | 0.802 | -0.662 | 0.738 | 2.177 | -3.306 | 0.938 | 1.677 | 1.139 | 0.7 | -36.006 | 0.778 | -5.929 | -0.055 | -0.944 | 1.689 |
| Operating Expenses
| 63.864 | 60.907 | 57.575 | 55.451 | 60.676 | 59.663 | 48.722 | 44.789 | 42.192 | 31.925 | 32.54 | 23.502 | 16.964 | 14.061 | 17.6 | 8.972 | 6.686 | 7.369 |
| Operating Income
| -58.839 | -56.844 | -53.948 | -52.334 | -58.583 | -58.259 | -47.71 | -43.86 | -42.192 | -31.925 | -32.54 | -23.502 | -16.964 | -14.061 | -17.6 | -8.972 | -6.686 | -7.369 |
| Operating Income Ratio
| -8.792 | -9.981 | -10.488 | -16.79 | -27.99 | -41.495 | -47.144 | -47.212 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 9.1 | 8.214 | 5.628 | 6.643 | -0.662 | 6.284 | 6.678 | -1.33 | 1.246 | 1.759 | 1.139 | 0.7 | -36.006 | 0.778 | -5.929 | -0.055 | -0.944 | 1.689 |
| Income Before Tax
| -49.739 | -48.63 | -48.32 | -45.691 | -53.807 | -51.975 | -41.032 | -45.19 | -40.946 | -30.166 | -31.337 | -22.749 | -52.965 | -13.263 | -23.531 | -8.99 | -7.58 | -5.603 |
| Income Before Tax Ratio
| -7.433 | -8.539 | -9.393 | -14.659 | -25.708 | -37.019 | -40.545 | -48.644 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.066 | 0.106 | 0.032 | -0.067 | 0.176 | -6.284 | 0.053 | 1.33 | -1.246 | -1.759 | -1.203 | -0.753 | 36.001 | -0.798 | 5.933 | 0.018 | 0.894 | -1.766 |
| Net Income
| -49.805 | -48.736 | -48.352 | -45.758 | -53.983 | -45.691 | -41.085 | -46.52 | -39.7 | -28.407 | -31.337 | -22.749 | -52.965 | -13.263 | -23.531 | -8.99 | -7.58 | -5.603 |
| Net Income Ratio
| -7.442 | -8.558 | -9.4 | -14.68 | -25.792 | -32.543 | -40.598 | -50.075 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.59 | -0.59 | -0.69 | -0.72 | -0.87 | -0.74 | -0.67 | -0.81 | -0.82 | -0.58 | -0.65 | -0.47 | -1.1 | -0.3 | -0.81 | -0.31 | -0.26 | -0.19 |
| EPS Diluted
| -0.59 | -0.59 | -0.69 | -0.72 | -0.87 | -0.74 | -0.67 | -0.81 | -0.82 | -0.58 | -0.65 | -0.47 | -1.1 | -0.3 | -0.81 | -0.31 | -0.26 | -0.19 |
| EBITDA
| -57.172 | -55.212 | -52.431 | -52.334 | -57.246 | -58.259 | -46.785 | -43.86 | -41.544 | -31.411 | -32.54 | -23.09 | -16.607 | -13.767 | -17.347 | -8.348 | -6.4 | -7.204 |
| EBITDA Ratio
| -8.543 | -9.695 | -10.193 | -16.79 | -27.351 | -41.495 | -46.23 | -47.212 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |